Skip to content
Inciteful Med
Resources About us Ask a Question

Is Active Surveillance Safe for Solitary Fibrous Tumors?

Published: | Updated:

Active surveillance, or 'watch and wait', can be a safe option for small, slow-growing solitary fibrous tumors (SFT) that cause no severe symptoms. It is often recommended when surgery is risky due to the tumor's location. This approach involves strict monitoring with regular imaging scans.

Key Takeaways

  • • While surgery is the standard treatment, active surveillance is a safe option for slow-growing, asymptomatic solitary fibrous tumors.
  • • Doctors often recommend watching and waiting if a tumor is located near delicate structures where surgery carries high risks of nerve damage or bleeding.
  • • Active surveillance requires strict, long-term monitoring with regular MRI or CT scans to track any changes in tumor size.
  • • Medical teams use tools like the Demicco risk score and biopsy results to ensure a tumor has low-risk characteristics before delaying surgery.
  • • If a monitored tumor begins to grow rapidly or causes new symptoms, the treatment plan will shift from surveillance to surgery.

Yes, while surgery is the standard and most common treatment for a solitary fibrous tumor (SFT) [1], there are certain situations where it is safe and appropriate to just “watch and wait” [2]. In the medical world, this approach is called active surveillance.

Because SFTs can behave unpredictably over time, doctors generally prefer to remove them completely whenever possible [3]. However, active surveillance may be recommended if your tumor is small, appears to be extremely slow-growing, and is located in an area where surgery poses a high risk to vital organs or nerves, such as near the brainstem, deep in the pelvis, or along the spine [4][5][2].

When is Active Surveillance Considered?

Your medical team will carefully weigh the risks of surgery against the risks of leaving the tumor in place. They may suggest active surveillance if your situation meets specific criteria:

  • No Severe Symptoms: To safely wait, the tumor must generally be “asymptomatic” (causing no symptoms) or only causing mild symptoms that do not interfere with your life. If a tumor is actively causing severe pain, organ compression, or neurological issues, surgery or other immediate treatment is usually necessary [6].
  • High-Risk Surgical Location: SFTs can grow anywhere in the body. If a tumor is located near delicate structures—like the brainstem, spinal cord, deep in the pelvis, or near major blood vessels—the immediate risks of surgery (such as permanent nerve damage or severe bleeding) might outweigh the benefits of removing a slow-growing tumor [7][8].
  • Low-Risk Tumor Characteristics: If you have had a biopsy, pathologists will look at the tumor cells under a microscope to calculate your risk level. They look for signs of aggressive behavior, such as a high mitotic rate (how fast the cells are dividing) or necrosis (areas of dead tumor cells) [9][10]. If these signs are absent or very low, the tumor is considered lower risk, making surveillance a safer option [2][6].
    • Note on Biopsies: If the tumor is in a very delicate, hard-to-reach location, a biopsy itself might be too dangerous. In these cases, your team might rely entirely on MRI or CT imaging to gauge the tumor’s growth rate and characteristics before deciding on surveillance [11].
  • Risk Scores: Doctors often use specific scoring systems, like the Demicco risk score, which combines your age, the size of the tumor, and biopsy results to predict how the tumor might behave [12][13]. A very low risk score can support a decision to delay surgery.

What Does “Watch and Wait” Actually Mean?

“Watch and wait” does not mean ignoring the tumor. Active surveillance is a structured, proactive process.

If you and your doctor choose this path, you will have regular, scheduled imaging scans (like MRIs or CT scans) to monitor the tumor’s size and check for any signs of growth or change [11][14]. Typically, these scans are done every 3 to 6 months initially. If the tumor remains perfectly stable over time, your doctor might spread these scans out to once a year [15]. Because SFTs can sometimes change their behavior or start growing years after they are first discovered, this long-term, vigilant monitoring is absolutely essential [16][17].

If a scan shows that the tumor is starting to grow faster, or if you begin to develop new symptoms due to the tumor pressing on nearby organs or nerves, your care team will likely recommend shifting from active surveillance to surgical treatment [6][1].

Frequently Asked Questions

What does watch and wait mean for a solitary fibrous tumor?
'Watch and wait,' medically known as active surveillance, means carefully monitoring your tumor with regular MRI or CT scans rather than undergoing immediate surgery. It is a highly proactive approach, not a way of ignoring the tumor.
When is active surveillance a safe option for SFT?
Surveillance may be recommended if your tumor is small, causes no major symptoms, and is located in an area where surgery poses serious risks to nerves or vital organs. Your doctor will also check if the tumor has low-risk characteristics.
What is a Demicco risk score?
The Demicco risk score is a medical tool that combines your age, the size of your tumor, and specific biopsy results to predict how aggressive the tumor might be. A very low risk score often supports the decision to safely delay surgery.
How often will I need scans during active surveillance?
If you and your doctor choose active surveillance, you will typically need an MRI or CT scan every 3 to 6 months at first. If the tumor remains completely stable, your medical team might spread these scans out to once a year.
What changes would trigger the need for SFT surgery?
Your care team will likely recommend surgery if a follow-up scan shows the tumor is growing faster. Surgery is also necessary if you develop new symptoms, such as severe pain, organ compression, or neurological issues like numbness.

Questions for Your Doctor

  • • Based on my tumor's location, what are the specific risks of attempting surgery right now versus waiting?
  • • Given where my tumor is located, is a biopsy safe, or should we rely on imaging to understand the tumor's behavior?
  • • Has a risk score, such as the Demicco score, been calculated for my tumor, and what does it indicate about my case?
  • • If we choose active surveillance, exactly how often will I need follow-up imaging scans during the first year?
  • • What specific changes on a scan, or what new physical symptoms, would trigger the decision to move forward with surgery?

Questions for You

  • • How comfortable am I with the psychological uncertainty of leaving the tumor in place compared to the immediate physical risks of a complex surgery?
  • • Am I currently experiencing any daily symptoms (like pain, numbness, or pressure) that are affecting my quality of life?
  • • What specific physical symptoms or nerve issues should prompt me to call the doctor's office before my next scheduled scan?
  • • Am I prepared to commit to a strict schedule of regular follow-up scans and medical appointments for the foreseeable future?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Hybrid Management of Giant Solitary Intracranial Fibrous Tumors: A Report of Two Cases.

    Alvis Peña DJ, Morales Baez JA, Espinosa Lira F, et al.

    Cureus 2025; (17(7)):e87798 doi:10.7759/cureus.87798.

    PMID: 40799885
  2. 2

    Solitary Fibrous Tumor of the Pancreas: A Case Report and Review of the Literature.

    Spasevska L, Janevska V, Janevski V, et al.

    Prilozi (Makedonska akademija na naukite i umetnostite. Oddelenie za medicinski nauki) 2016; (37(2-3)):115-120.

    PMID: 27883325
  3. 3

    Solitary fibrous tumor of the liver: A case report and review of the literature.

    Xie GY, Zhu HB, Jin Y, et al.

    World journal of clinical cases 2022; (10(20)):7097-7104 doi:10.12998/wjcc.v10.i20.7097.

    PMID: 36051139
  4. 4

    Intracranial Solitary Fibrous Tumor/Hemangiopericytoma: A Series of 14 Cases and Review of the Literature.

    Toader C, Arsene D, Popa AA, et al.

    Cureus 2024; (16(5)):e59798 doi:10.7759/cureus.59798.

    PMID: 38846236
  5. 5

    A case of lumbar spinal solitary fibrous tumor or hemangiopericytomas.

    Alkulli OA, Albaradie OA, Alghamdi KT, et al.

    Surgical neurology international 2024; (15()):301 doi:10.25259/SNI_538_2024.

    PMID: 39246775
  6. 6

    Evaluation of Alternative Risk Stratification Systems in a Large Series of Solitary Fibrous Tumors with Molecular Findings and Ki-67 Index Data: Do They Improve Risk Assessment?

    Machado I, Blázquez Bujeda Á, Giner F, et al.

    International journal of molecular sciences 2022; (24(1)) doi:10.3390/ijms24010439.

    PMID: 36613891
  7. 7

    Solitary fibrous tumor arising from pelvic retroperitoneum: A report of two cases and a review of the literature.

    Yamada K, Abiko K, Kido A, et al.

    The journal of obstetrics and gynaecology research 2019; (45(7)):1391-1397 doi:10.1111/jog.13965.

    PMID: 30957324
  8. 8

    A review of solitary fibrous tumor/hemangiopericytoma tumor and a comparison of risk factors for recurrence, metastases, and death among patients with spinal and intracranial tumors.

    Giordan E, Marton E, Wennberg AM, et al.

    Neurosurgical review 2021; (44(3)):1299-1312 doi:10.1007/s10143-020-01335-x.

    PMID: 32556679
  9. 9

    Solitary Fibrous Tumors of the Female Genital Tract: A Study of 27 Cases Emphasizing Nonvulvar Locations, Variant Histology, and Prognostic Factors.

    Devins KM, Young RH, Croce S, et al.

    The American journal of surgical pathology 2022; (46(3)):363-375 doi:10.1097/PAS.0000000000001829.

    PMID: 34739418
  10. 10

    Recurrence of Solitary Fibrous Tumor/Hemangiopericytoma Could Be Predicted by Ki-67 Regardless of Its Origin.

    Yamamoto Y, Hayashi Y, Murakami I

    Acta medica Okayama 2020; (74(4)):335-343 doi:10.18926/AMO/60372.

    PMID: 32843765
  11. 11

    Pathological Features and Clinical Course in Patients With Recurrent or Malignant Orbital Solitary Fibrous Tumor/Hemangiopericytoma.

    Sagiv O, Bell D, Guo Y, et al.

    Ophthalmic plastic and reconstructive surgery 2019; (35(2)):148-154 doi:10.1097/IOP.0000000000001189.

    PMID: 30371551
  12. 12

    Risk assessment in solitary fibrous tumors: validation and refinement of a risk stratification model.

    Demicco EG, Wagner MJ, Maki RG, et al.

    Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2017; (30(10)):1433-1442 doi:10.1038/modpathol.2017.54.

    PMID: 28731041
  13. 13

    Comparison of published risk models for prediction of outcome in patients with extrameningeal solitary fibrous tumour.

    Demicco EG, Griffin AM, Gladdy RA, et al.

    Histopathology 2019; (75(5)):723-737 doi:10.1111/his.13940.

    PMID: 31206727
  14. 14

    Solitary Fibrous Tumors of the Head and Neck: A Single-Institution Study of 52 Patients.

    Chung HR, Tam K, Han AY, et al.

    OTO open 2022; (6(3)):2473974X221098709 doi:10.1177/2473974X221098709.

    PMID: 35845143
  15. 15

    Malignant recurrent orbital solitary fibrous tumor.

    Pol JN, Patil DB, Desai SS, Calcuttawala AB

    Indian journal of pathology & microbiology 2023; (66(4)):819-822 doi:10.4103/ijpm.ijpm_713_21.

    PMID: 38084539
  16. 16

    Long-Term Surgical Outcome for Orbital Solitary Fibrous Tumors.

    Vahdani K, Rose GE, Verity DH

    Ophthalmic plastic and reconstructive surgery 2023; (39(6)):606-613 doi:10.1097/IOP.0000000000002446.

    PMID: 37405750
  17. 17

    Metastatic intracranial solitary fibrous tumors/hemangiopericytomas: description of two cases with radically different behaviors and review of the literature.

    Lavacchi D, Antonuzzo L, Briganti V, et al.

    Anti-cancer drugs 2020; (31(6)):646-651 doi:10.1097/CAD.0000000000000900.

    PMID: 31972591

This page explains active surveillance for solitary fibrous tumors for educational purposes only. Always consult your oncology and surgical team to determine if a watch-and-wait approach is medically safe for your specific tumor.

Stay up to date

Get notified when new research about Solitary Fibrous Tumor (SFT) is published.

No spam. Unsubscribe anytime.